Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 10/20 | 0.51 |
| ▸ | CA12 | O43570 | 7/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48794 | 0.80 | SIGMAR1 (0.53) | CYP2A6CA2CA12PDE10ASIGMAR1 | |
| SCHEMBL48037 | 0.78 | SIGMAR1 (0.57) | CYP2A6CA2CA12PDE10ASIGMAR1 | |
| SCHEMBL3144878 | 0.78 | CYP2A6 (0.59) | CYP2A6CA2CA12PDE10AMRGPRX4 | |
| SCHEMBL28707496 | 0.75 | CYP2A6 (0.51) | CYP2A6CA2CA12PDE10A | |
| SCHEMBL29469352 | 0.75 | CYP2A6 (0.51) | CYP2A6CA2CA12PDE10A | |
| SCHEMBL5547137 | 0.74 | CYP2A6 (0.54) | CYP2A6CA2CA12PDE10AMRGPRX4 | |
| SCHEMBL2962869 | 0.73 | CYP2A6 (0.53) | CYP2A6CA2CA12PDE10AMRGPRX4 | |
| SCHEMBL4952656 | 0.73 | CA2 (0.58) | CA2CA12PTPN11 | |
| SCHEMBL25226263 | 0.73 | CA2 (0.36) | CA2SIGMAR1 | |
| SCHEMBL16727006 | 0.73 | CYP2A6 (0.39) | CYP2A6CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009111501-A1 | DERIVATIVES OF IMIDAZO [4, 5-D] PYRIDAZINE AND THEIR USE AS ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-09-10 | — | — | US | disclosed |
| US-20050209274-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABOTT LABORATORIES | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209274-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | CYP2A6 2701/4885CA2 2859/4885CA12 3894/4885 |
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | MAVS, SARS1, HAVCR2 | CYP2A6 947/4885CA2 1373/4885CA12 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.